200 Berkeley Street
Office 19th Floor
Boston, MA 02116
United States
857 702 9600
https://www.neurobopharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Hyung-Heon Kim | CEO, President, Principal Executive & Director | 54.22k | N/A | 1975 |
Mr. Marshall H. Woodworth | CFO, Principal Financial Officer & Principal Accounting Officer | N/A | N/A | 1958 |
Dr. Mi-Kyung Kim | Chief Scientific Officer | N/A | N/A | N/A |
Mr. Robert Homolka | Senior Vice President of Clinical Operations | N/A | N/A | N/A |
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
NeuroBo Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.